Altimmune, Inc. - 8-K Filing

Altimmune reports Q3 2026 net loss of $31.6 million and maintains $480 million in cash and investments. (Items: 2.02 Results of Operations and Financial ConditionOn November 12, 2026, Altimmune, Inc, 9.01 Financial Statements and Exhibits​(d) Exhibits​​​No)

3 articles from 1 source · updated November 12, 2026, 13:21 UTC

Coverage

• Corvex, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:21 UTC
• CorMedix Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:00 UTC
• Altimmune, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 12:33 UTC